Literature DB >> 30277116

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Margaret Nieborowska-Skorska1, Silvia Maifrede1, Min Ye2, Monika Toma1,3, Elizabeth Hewlett2, John Gordon2, Bac Viet Le1,4, Tomasz Sliwinski3, Huaqing Zhao5, Katarzyna Piwocka4, Peter Valent6, Alexei V Tulin7, Wayne Childers2, Tomasz Skorski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30277116      PMCID： PMC6445778          DOI： 10.1080/10428194.2018.1520988

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Authors:  Paulina Podszywalow-Bartnicka; Magdalena Wolczyk; Monika Kusio-Kobialka; Kamila Wolanin; Krzysztof Skowronek; Margaret Nieborowska-Skorska; Yashodhara Dasgupta; Tomasz Skorski; Katarzyna Piwocka
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

2.  Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-ribosyl)ation.

Authors:  Colin J Thomas; Elena Kotova; Mark Andrake; Jared Adolf-Bryfogle; Robert Glaser; Catherine Regnard; Alexei V Tulin
Journal:  Mol Cell       Date:  2014-02-06       Impact factor: 17.970

Review 3.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Authors:  Christopher J Lord; Andrew N J Tutt; Alan Ashworth
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

4.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.

Authors:  Fatima Dkhissi; Djamel Aggoune; Julien Pontis; Nathalie Sorel; Nathalie Piccirilli; Amélie LeCorf; François Guilhot; Jean-Claude Chomel; Slimane Ait-Si-Ali; Ali G Turhan
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

6.  Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase.

Authors:  Ketki Karanam; Ran Kafri; Alexander Loewer; Galit Lahav
Journal:  Mol Cell       Date:  2012-07-27       Impact factor: 17.970

7.  Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair.

Authors:  Alexander W Bird; David Y Yu; Marilyn G Pray-Grant; Qifeng Qiu; Kirsty E Harmon; Paul C Megee; Patrick A Grant; M Mitchell Smith; Michael F Christman
Journal:  Nature       Date:  2002-09-26       Impact factor: 49.962

Review 8.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

9.  Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.

Authors:  Colin Thomas; Yingbiao Ji; Niraj Lodhi; Elena Kotova; Aaron Dan Pinnola; Konstantin Golovine; Peter Makhov; Kate Pechenkina; Vladimir Kolenko; Alexei V Tulin
Journal:  EBioMedicine       Date:  2016-10-04       Impact factor: 8.143

10.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312
View more
  5 in total

1.  Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Authors:  Yaroslava Karpova; Chao Wu; Ali Divan; Mark E McDonnell; Elizabeth Hewlett; Peter Makhov; John Gordon; Min Ye; Allen B Reitz; Wayne E Childers; Tomasz Skorski; Vladimir Kolenko; Alexei V Tulin
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

2.  Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.

Authors:  Elizabeth Hewlett; Monika Toma; Katherine Sullivan-Reed; John Gordo; Tomasz Sliwinski; Alexei Tulin; Wayne E Childers; Tomasz Skorski
Journal:  Med Chem Res       Date:  2020-04-19       Impact factor: 1.965

Review 3.  Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.

Authors:  Peter Makhov; Robert G Uzzo; Alexei V Tulin; Vladimir M Kolenko
Journal:  Urol Oncol       Date:  2020-05-08       Impact factor: 2.954

Review 4.  RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.

Authors:  Monika Toma; Katherine Sullivan-Reed; Tomasz Śliwiński; Tomasz Skorski
Journal:  Cancers (Basel)       Date:  2019-10-14       Impact factor: 6.639

Review 5.  DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1.

Authors:  Rakesh Srivastava; Niraj Lodhi
Journal:  Biomolecules       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.